...
首页> 外文期刊>Medicine. >Prognostic significance of X-linked inhibitor of apoptosis protein in patients with gastrointestinal tract cancers: A meta-analysis
【24h】

Prognostic significance of X-linked inhibitor of apoptosis protein in patients with gastrointestinal tract cancers: A meta-analysis

机译:胃肠道癌患者呼吸凋亡蛋白X型抑制剂的预后意义:META分析

获取原文

摘要

Background: The aim of this meta-analysis was to systematically evaluate the prognostic significance of X-linked inhibitor of apoptosis protein (XIAP) in patients with gastrointestinal tract (GIT) cancers. Methods: PubMed, Web of Science, EMBASE, Cochrane Library and China National Knowledge Infrastructure were searched for potentially eligible literature. The baseline characteristics and relevant data were extracted. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to assess the prognostic role of XIAP in patients with GIT cancers. Results: Twelve studies with 2,477 patients were included. The pooled HRs of higher expression of XIAP for overall survival (OS) and recurrence free survival (RFS) in patients with GIT cancers were 1.64 (95% CI, 1.27–2.13) and 1.06 (95% CI, 0.96–1.16), respectively. Subgroup analysis and sensitivity analysis were also performed. No significant publication bias was found. Conclusion: Our results suggested that XIAP could be a prognostic marker for OS but not RFS in patients with GIT cancers. Higher expression of XIAP was related to poorer OS. These findings may help evaluate the prognosis of patients and assist future research on novel therapeutic strategies of GIT cancers by targeting XIAP. However, more well-designed studies are warranted to verify the results.
机译:背景:这种荟萃分析的目的是系统地评估胃肠道患者胃肠道(GIT)癌症患者癫痫蛋白(XIAP)的X型抑制剂的预后意义。方法:搜查了Pubmed,Embase,Cochrane图书馆和中国国家知识基础设施的PubMed,潜在的合格文献。提取基线特征和相关数据。估计危害比率(HRS)和95%置信区间(CIS)评估XIAP在GIT癌症患者中的预后作用。结果:包括2,477名患者的12项研究。 GIT癌症患者的整体存活(OS)和复发自由存活(RFS)的汇集HRS分别为1.64(95%CI,1.27-2.13)和1.06(95%CI,0.96-1.16) 。还进行了亚组分析和敏感性分析。没有发现任何重大出版物偏见。结论:我们的研究结果表明,XIAP可能是OS的预后标志物,但没有GIT癌症患者的RFS。 XIAP的更高表达与较差的操作系统有关。这些发现可能有助于评估患者的预后,并通过针对XIAP对GIT癌的新药治疗策略进行帮助。然而,有必要精心设计的研究来验证结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号